- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
Patent holdings for IPC class C07K 14/715
Total number of patents in this class: 2904
10-year publication summary
|
115
|
206
|
183
|
228
|
272
|
265
|
319
|
295
|
250
|
119
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4698 |
107 |
| Altor BioScience, LLC | 79 |
57 |
| Xencor, Inc. | 412 |
44 |
| Immunitybio, Inc. | 507 |
40 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2999 |
38 |
| The Trustees of the University of Pennsylvania | 4414 |
34 |
| The Board of Trustees of the Leland Stanford Junior University | 6644 |
33 |
| Vib VZW | 902 |
28 |
| Synthekine, Inc. | 119 |
28 |
| National University of Singapore | 2582 |
27 |
| The Regents of the University of California | 20720 |
25 |
| Cytune Pharma | 40 |
25 |
| Dana-Farber Cancer Institute, Inc. | 2662 |
25 |
| Universiteit Gent | 1401 |
25 |
| Amgen Inc. | 4425 |
24 |
| FATE Therapeutics, Inc. | 235 |
24 |
| Singapore Health Services Pte Ltd | 489 |
23 |
| Autolus Limited | 266 |
22 |
| Novartis AG | 10263 |
21 |
| Bristol-myers Squibb Company | 4729 |
19 |
| Other owners | 2235 |